Aripiprazole: a treatment for severe coprolalia in "refractory" Gilles de la Tourette syndrome

Mov Disord. 2008 Feb 15;23(3):438-40. doi: 10.1002/mds.21859.

Abstract

Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28-year-old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antipsychotic Agents / therapeutic use*
  • Aripiprazole
  • Humans
  • Male
  • Piperazines / therapeutic use*
  • Quinolones / therapeutic use*
  • Tourette Syndrome / drug therapy*
  • Treatment Outcome

Substances

  • Antipsychotic Agents
  • Piperazines
  • Quinolones
  • Aripiprazole